Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine

Nomy Levin-Iaina, Avital Angel-Korman, Adi Leiba, Esther Peres, Gabriel Bryk, Vladimir Rapoport, Zeev Katzir, Yoram Yagil, Tal Brosh-Nissimov

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The reduced immune response of maintenance hemodialysis patients to coronavirus disease 2019 (COVID-19) vaccines is a major concern. Objectives: To analyze the late (6 months after full vaccination) antibody response and compare it to early post-vaccination titer. Methods: We conducted a multicenter prospective study of 13 hemodialysis units in Israel. Results: We demonstrated that the low titers observed among ESRD patients 2-3 months after vaccination with the Comirnaty vaccine (median 63.8 AU/ml) declined to critically lower values 6 months after full vaccination. (Median anti-S antibodies, 31 AU/ml). Seropositivity significantly declined among hemodialysis patients from 89% to 74% (P < 0.0001), although it did not significantly change among controls. Conclusions: We recommend all patients on hemodialysis receive a booster COVID-19 vaccine 6 months after the second dose.

Original languageEnglish
Pages (from-to)317-319
Number of pages3
JournalIsrael Medical Association Journal
Volume24
Issue number5
StatePublished - 1 May 2022
Externally publishedYes

Keywords

  • Comirnaty vaccine
  • anti-S antibodies
  • coronavirus disease 2019 (COVID-19)
  • hemodialysis
  • humoral response

ASJC Scopus subject areas

  • Medicine (all)

Fingerprint

Dive into the research topics of 'Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine'. Together they form a unique fingerprint.

Cite this